MRK vs ZNTL
MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas. ZNTL: Zentalis Pharmaceuticals is developing azenosertib, a potentially first-in-class, oral, small-molecule WEE1 inhibitor as a targeted treatment for ovarian and other solid tumors.
Side-by-side fundamentals
| Metric | MRK | ZNTL | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $148.30 | $2.39 | |
| Market cap | $365.9B | $171M | |
| P/E as of 2026-10-20 | 118.64 | n/a | |
| Net margin FY2025, SEC XBRL | +28.1% | n/a | |
| ROE FY2025, SEC XBRL | +34.7% | -63.4% | MRK higher |
| ROA FY2025, SEC XBRL | +13.3% | -47.4% | MRK higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 1.29 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +1.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +3.1% | n/a | |
| Dividend yield as of 2026-09-03 | +2.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 19 | 0 | MRK higher |
| Beta as of 2026-09-03 | 0.29 | 1.66 | |
| 1-year return as of 2026-10-20 close | +71.8% | +54.2% | MRK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.